Aminex Therapeutics, Inc.

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm	Recruiting	Phase 1 / Phase 2	2026-09-04		NCT07287917
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas	Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, atypical teratoid rhabdoid tumor, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, diffuse intrinsic pontine glioma, embryonal tumor with multilayered rosettes, epithelial neoplasm, glioma, mixed neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdoid tumor, sarcoma	Recruiting	Phase 1 / Phase 2	2026-09-03		NCT06465199

Clinical trials